Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease-Reference-Cited by-同舟云学术

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Published:2018-01-25 Issue:4 Volume:378 Page:321-330
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Honig Lawrence S.¹,Vellas Bruno¹,Woodward Michael¹,Boada Mercè¹,Bullock Roger¹,Borrie Michael¹,Hager Klaus¹,Andreasen Niels¹,Scarpini Elio¹,Liu-Seifert Hong¹,Case Michael¹,Dean Robert A.¹,Hake Ann¹,Sundell Karen¹,Poole Hoffmann Vicki¹,Carlson Christopher¹,Khanna Rashna¹,Mintun Mark¹,DeMattos Ronald¹,Selzler Katherine J.¹,Siemers Eric¹

Affiliation:

1. From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research Center...

Funder

Eli Lilly and Company

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1705971

Cited by 837 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of gasotransmitters in necroptosis;Experimental Cell Research;2024-10

2. Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials;Brain;2024-09-11

3. Human neural stem cell-derived artificial organelles to improve oxidative phosphorylation;Nature Communications;2024-09-08

4. A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical Trials;2024-09-04

5. Understanding the impact of slowing disease progression for individuals with biomarker-confirmed early symptomatic Alzheimer’s disease;Current Medical Research and Opinion;2024-09